78318-44-2 Usage
Uses
Used in Pharmaceutical Industry:
ETHYL 4-METHYL-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure containing a morpholine ring and a pyrimidine ring, which are beneficial for medicinal chemistry research.
Used in Cardiovascular Applications:
ETHYL 4-METHYL-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is used as a potential antihypertensive agent for its therapeutic effects on hypertension and other cardiovascular disorders, as it has been studied for its potential to mitigate these conditions.
Used in Research and Development:
ETHYL 4-METHYL-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is used in research and development for exploring its potential applications in medicinal chemistry, given its structural features that make it a promising candidate for the development of new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 78318-44-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,3,1 and 8 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 78318-44:
(7*7)+(6*8)+(5*3)+(4*1)+(3*8)+(2*4)+(1*4)=152
152 % 10 = 2
So 78318-44-2 is a valid CAS Registry Number.
78318-44-2Relevant academic research and scientific papers
Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors
Scott, James S.,Gill, Adrian L.,Godfrey, Linda,Groombridge, Sam D.,Rees, Amanda,Revill, John,Schofield, Paul,S?rme, Pernilla,Stocker, Andrew,Swales, John G.,Whittamore, Paul R.O.
, p. 6756 - 6761 (2013/01/14)
11β-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11β-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution.
